Sept 30 Depomed Inc said a court ruled
in favor of the drug maker in a patent litigation over its
opioid drug, Nucynta, extending its market exclusivity until
The ruling comes weeks after sources told Reuters that
Depomed's talks with potential buyers are expected to start
shortly after the court decided on Nucynta, the company's
Activist investor Starboard Value LP in April called on
Depomed to explore a sale after announcing it had accumulated a
stake of close to 10 percent.
The court's ruling provides market exclusivity to Nucynta
ER, Nucynta and Nucynta oral solution, an unmarketed form of
Nucynta, the company said on Friday.
(Reporting by Dipika Jain in Bengaluru; Editing by Sriraj